BAJAJHCARE Stock Overview
A pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Bajaj HealthCare Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹552.90 |
52 Week High | ₹615.00 |
52 Week Low | ₹263.30 |
Beta | 0.51 |
1 Month Change | 38.64% |
3 Month Change | 44.38% |
1 Year Change | 47.34% |
3 Year Change | 37.45% |
5 Year Change | n/a |
Change since IPO | 52.34% |
Recent News & Updates
Bajaj HealthCare Limited (NSE:BAJAJHCARE) Stock Rockets 46% As Investors Are Less Pessimistic Than Expected
Dec 19Estimating The Intrinsic Value Of Bajaj HealthCare Limited (NSE:BAJAJHCARE)
Dec 10Recent updates
Bajaj HealthCare Limited (NSE:BAJAJHCARE) Stock Rockets 46% As Investors Are Less Pessimistic Than Expected
Dec 19Estimating The Intrinsic Value Of Bajaj HealthCare Limited (NSE:BAJAJHCARE)
Dec 10Bajaj HealthCare's (NSE:BAJAJHCARE) Dividend Will Be ₹1.00
Sep 12Bajaj HealthCare Limited (NSE:BAJAJHCARE) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Jul 12Bajaj HealthCare (NSE:BAJAJHCARE) Has Announced That Its Dividend Will Be Reduced To ₹1.00
Sep 10We Think That There Are More Issues For Bajaj HealthCare (NSE:BAJAJHCARE) Than Just Sluggish Earnings
Nov 19Bajaj HealthCare Limited (NSE:BAJAJHCARE) Soars 30% But It's A Story Of Risk Vs Reward
Jan 17Shareholder Returns
BAJAJHCARE | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | -5.5% | 0.2% | -2.5% |
1Y | 47.3% | 38.1% | 17.9% |
Return vs Industry: BAJAJHCARE exceeded the Indian Pharmaceuticals industry which returned 38.1% over the past year.
Return vs Market: BAJAJHCARE exceeded the Indian Market which returned 17.9% over the past year.
Price Volatility
BAJAJHCARE volatility | |
---|---|
BAJAJHCARE Average Weekly Movement | 9.9% |
Pharmaceuticals Industry Average Movement | 6.0% |
Market Average Movement | 6.2% |
10% most volatile stocks in IN Market | 9.1% |
10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: BAJAJHCARE's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: BAJAJHCARE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 1,049 | Sajankumar Bajaj | www.bajajhealth.com |
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, venous disease, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, lipotropic agents, nootropic, vasoprotective/antihemorrhagic, cardiovascular agents, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It provides intermediates, such as guanine, 3-methyl xanthine, bromoethyl theophylline, calcium phosphoryl choline chloride, 4-hydrazinobenzoic acid, ticagrelor acetonide, 4,7-dichloroquinolone, 5-[N-ethyl-N-(2-hydroxyethyl)amino]-2-aminopentane, 2-amino -4-hydroxyacetophenone, 8- chloro theophylline, 8 bromo-3-methyl xanthine, 3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine, (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile, 3 – amino – 1 – adamantanol, N – boc -sitagliptin, sitagliptin base, hesperidine, (2,7-dichlori-9H-fluorene), (2-Chloro-1-(2,7- dichlori-9H-fluoren-4-yl)ethanone), (2-(dibutylamino)-1-(2, 7- dichlori-9H-fluoren-4-yl)ethanol), (2-Nitro-4-thiocyanoaniline), 4- (propylthio) benzene -1,2-diamine, methyl [(E)amino(methylsulfanyl)methylidene] carbamate, and (2-phenoxy methane sulphonamide).
Bajaj HealthCare Limited Fundamentals Summary
BAJAJHCARE fundamental statistics | |
---|---|
Market cap | ₹17.90b |
Earnings (TTM) | -₹101.06m |
Revenue (TTM) | ₹5.08b |
3.4x
P/S Ratio-172.9x
P/E RatioIs BAJAJHCARE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BAJAJHCARE income statement (TTM) | |
---|---|
Revenue | ₹5.08b |
Cost of Revenue | ₹2.69b |
Gross Profit | ₹2.39b |
Other Expenses | ₹2.49b |
Earnings | -₹101.06m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.20 |
Gross Margin | 46.99% |
Net Profit Margin | -1.99% |
Debt/Equity Ratio | 46.0% |
How did BAJAJHCARE perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield-19%
Payout RatioCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/26 15:13 |
End of Day Share Price | 2024/12/26 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bajaj HealthCare Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|